Recent Cases
10 July 2008 - Novartis buys additional 51.7% stake in Speedel and announces plans to acquire remaining shares in a mandatory public tender offer
On 9 July 2008, Novartis acquired an additional 51.7% stake in Speedel, a listed Swiss biopharmaceutical company through a series of off-exchange transactions with major Speedel shareholders for approx. CHF 525 million in cash. Novartis will commence a mandatory tender offer to acquire the remaining shares of Speedel and Speedel's activities are planned to be integrated into Novartis.
Bär & Karrer is advising Novartis in this matter; Novartis' inhouse legal team is headed by Jörg Walther, global head legal M&A and Antitrust. The Bär & Karrer team comprises the partners Rolf Watter and Dieter Dubs and the associates Philippe A. Huber and Katja Roth Pellanda.